HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

mifobate (SR 202)

has antiatherosclerotic properties

Also Known As:

SR 202; SR-202; (4-chlorophenyl)(dimethoxyphosphinyl)methylphosphoric acid dimethyl ester; Clenicor; dimethyl alpha-(dimethoxyphosphinyl)-4-chlorobenzyl phosphate

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - mifobate: 3

Experts

1.	Campos, Jéssica L O: 1 article (11/2013)
2.	Figueira, Ana Carolina M: 1 article (11/2013)
3.	Mafud, Ana Carolina: 1 article (11/2013)
4.	Nascimento, Alessandro S: 1 article (11/2013)
5.	Polikarpov, Igor: 1 article (11/2013)
6.	da Silva, Flávia M C: 1 article (11/2013)
7.	dos Santos, Jademilson C: 1 article (11/2013)
8.	Doggrell, Sheila: 1 article (04/2003)
9.	Desvergne, Béatrice: 1 article (11/2002)
10.	Escher, Pascal: 1 article (11/2002)

Related Diseases

1.	Insulin Resistance 11/01/2013 - "Additionally, two previously described receptor antagonists, SR-202 and BADGE, were also shown to improve insulin sensitivity and decrease TNF-α level, revealing that receptor antagonism may also be an approach to pursue. " 11/01/2002 - "Treatment with SR-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice. " 11/01/2002 - "In vivo, decreasing PPARgamma activity, either by treatment with SR-202 or by invalidation of one allele of the PPARgamma gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance. " 04/01/2003 - "Feeding mice with a high-fat diet induced insulin resistance measured as increased plasma levels of glucose, insulin and free fatty acids, and SR-202 protected against these changes. "
2.	Obesity 11/01/2002 - "Because it yields both antiobesity and antidiabetic effects, SR-202 may be a lead for new compounds to be used in the treatment of obesity and type 2 diabetes."
3.	Hypertrophy 11/01/2002 - "In vivo, decreasing PPARgamma activity, either by treatment with SR-202 or by invalidation of one allele of the PPARgamma gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance. "
4.	Type 2 Diabetes Mellitus (MODY) 11/01/2002 - "Because it yields both antiobesity and antidiabetic effects, SR-202 may be a lead for new compounds to be used in the treatment of obesity and type 2 diabetes."

Related Drugs and Biologics

1.	PPAR gamma
2.	Insulin (Novolin)
3.	Hypoglycemic Agents (Hypoglycemics)
4.	Glucose (Dextrose)
5.	Nonesterified Fatty Acids (NEFA)